$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

2025-07-03

2027-02-28

2027-05-31

120

Study Overview

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.

This is a multicenter Phase 1, open-label study to evaluate the safety, tolerability, pharmacokinetic profile, and initial efficacy of BLM05D1 in subjects with unresectable locally advanced or metastatic solid tumors of the digestive system and other solid tumors who have received at least 2 lines of standard therapy, including adjuvant/neoadjuvant treatment, or whose cancer is considered refractory to the standard of care or for which no standard treatment is available. This study will be conducted in three parts (dose escalation, dose finding and dose expansion). Subjects will be dosed on Day 1 on a continuous 21-day treatment cycle.

  • Gastric Adenocarcinoma
  • Advanced Pancreatic Ductal Adenocarcinoma
  • Esophageal Adenocarcinoma
  • Mucinous Ovarian Adenocarcinoma
  • Other Solid Tumors
  • DRUG: BL-M05D1
  • BL-M05D1-ST-101

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2025-05-23  

N/A  

2025-06-05  

2025-06-05  

N/A  

2025-06-13  

2025-06-13  

N/A  

2025-06  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Sequential

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Experimental BL-M05D1 administered Day 1 per cycle

BL-M05D1 will be administered on Day 1 by intravenous (IV) infusion every 3 weeks

DRUG: BL-M05D1

  • BL-M05D1 will be administered on D1 every 3 weeks.
Primary Outcome MeasuresMeasure DescriptionTime Frame
Participants with Dose-limiting toxicitiesA DLT is defined as the following: Toxicity that results in a >14-day delay in treatment - Hematologic toxicities Grade 4 neutrophil count decreased lasting >7 days Grade ≥3 febrile neutropenia of any duration Grade ≥3 platelet count decreased with clinically significant hemorrhage Grade 4 thrombocytopenia lasting >7 days - Nonhematologic toxicities Death not clearly related to disease progression or extraneous cause Hy's law cases Grade ≥3 nonhematologic toxicities, except for: Grade 3 nausea/vomiting or diarrhea for less than 72 hours with adequate antiemetic and other supportive care Grade 3 fatigue for less than 1 week Grade ≥3 electrolyte abnormality that lasts up to 72 hours, is not clinically complicated, and resolves spontaneously or responds to conventional medical interventions Grade ≥3 amylase or lipase that is not associated with symptoms or clinical manifestations of pancreatitis1 year
Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs)Measuring the number of patients with serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)1 year
Participants with abnormal physical examination findingsMeasure the number of participants with abnormal physical examination findings.1 year
Participants with ability to care for themselves, daily activity, and physical activityMeasure the change in participants with Eastern Clinical Oncology Group (ECOG) Scale of Performance Status. The scale is 0-4 with 0 being the fully active (best outcome) and 4 being completely disabled (worst outcome)1 year
Participants with abnormal ECG and ECHO/MUGA readingPatients with abnormal ECG parameters (including the change from-baseline ECG parameters: heart rate [HR]; PR; QTcF; and QRS intervals [∆HR, ∆PR, ∆QTcF, and ∆QRS]), and ECHO/MUGA findings1 year
Participants with abnormal lab resultsMeasure the number of participants with abnormal clinical laboratory values1 year
To determine the maximum tolerated dose (MTD) if reached or maximum administered dose (MAD) and two or more recommended doses for expansion (RDEs) of BL-M05D1 in metastatic or unresectable tumorsThe actual number of subjects enrolled and dose levels to be explored in this study will depend on the MTD and/or RDE based on DLTs reported during the DLT observation period.1 year
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Cmax of BL-M05D1Calculate maximum (peak) observed concentration of BL-M05D11 year
Cmax of anti-BL-M05D1 antibodiesCalculate maximum (peak) observed concentration of anti-BL-M05D1 antibodies1 year
Cmax of free payload ED-04Calculate maximum (peak) observed concentration of free payload ED-041 year
Tmax of BL-M05D1Calculate time of maximum observed concentration of BL-M05D11 year
Tmax of anti-BL-M05D1 antibodiesCalculate time of maximum observed concentration of anti-BL-M05D1 antibodies1 year
Tmax of free payload ED-04Calculate time of maximum observed concentration of free payload ED-041 year
AUC(0-8) of BL-M05D1Calculate area under the serum concentration-time curve of BL-M05D1 from time 0 to 8 hours1 year
AUC(0-8) of anti-BL-M05D1 antibodiesCalculate area under the serum concentration-time curve of anti-BL-M05D1 antibodies from time 0 to 8 hours1 year
AUC(0-8) of free payload ED-04Calculate area under the serum concentration-time curve of free payload ED-04 from time 0 to 8 hours1 year
AUC(last) of BL-M05D1Calculate area under the serum concentration-time curve up of BL-M05D1 to the last quantifiable time0 to 8 hours1 year
AUC(last) of anti-BL-M05D1 antibodiesCalculate area under the serum concentration-time curve up of anti-BL-M05D1 antibodies to the last quantifiable time0 to 8 hours1 year
AUC(last) of free payload ED-04Calculate area under the serum concentration-time curve up of free payload ED-04 to the last quantifiable time1 year
Overall Response Rate (ORR)To assess the clinical efficacy of BL-M05D1 as measured by ORR using RECIST criteria v 1.11 year
Disease Control Rate (DCR)To assess the clinical efficacy of BL-M05D1 as measured by DCR using RECIST criteria v 1.11 year
Time To Response (TTR)To assess the clinical efficacy of BL-M05D1 as measured by TTR using RECIST criteria v 1.11 year
Progression-Free Survival (PFS)To assess the clinical efficacy of BL-M05D1 as measured by PFS using RECIST criteria v 1.11 year
Overall Survival (OS)To assess the clinical efficacy of BL-M05D1 as measured by OS using RECIST criteria v 1.11 year
Duration of response (DoR)To assess the clinical efficacy of BL-M05D1 as measured by DoR using RECIST criteria v 1.11 year

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Murielle Carre

Phone Number: 425.453.6841

Email: murielle.carre@systimmune.com

Study Contact Backup

Name: Whitney Eakins

Phone Number: 425.453.6841

Email: whitney.eakins@systimmune.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Signed the informed consent voluntarily and agreed to follow the program requirements 2. Age: ≥18 years 3. Has a life expectancy of ≥3 months 4. Has documented locally advanced or metastatic solid tumor(s) with radiographic progression on the latest line of therapy, not amenable to curative surgery or radiation, including:
    1. Cohort 1 (Parts 1 to 3): Subjects with gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (AC) who have received at least 2 lines of standard therapy, including adjuvant/neoadjuvant treatment, or whose cancer is considered refractory to standard of care or for which no standard treatment is available.
    Subjects with HER2, PD-L1 and/or microsatellite instability high (MSI-H)/ mismatch repair deficiency (dMMR) positive tumors must have received targeted treatment in their prior lines of therapy. 2. Cohort 2 (Parts 1 to 3): Subjects with advanced pancreatic ductal AC (PDAC) who have received at least one line of standard therapy. Subjects may enter screening prior to completing the first line of standard therapy. 3. Cohort 3 (Parts 1 to 2 only): Subjects with esophageal AC (EAC) who have received at least 2 lines of standard therapy, including adjuvant/neoadjuvant treatment, or whose cancer is considered refractory to standard of care or for which no standard treatment is available. Subjects with HER2, PD-L1 and/or MSI-H/dMMR positive tumors must have received targeted treatment in their prior lines of therapy. 4. Cohort 4 (Parts 1 to 2 only): Subjects with primary mucinous ovarian AC (MOAC) or metastatic MOAC originating in the upper gastrointestinal tract who have received at least 2 lines of standard therapy, including adjuvant/neoadjuvant treatment, or whose cancer is considered refractory to standard of care or for which no standard treatment is available. 5. Cohort 5 (Parts 1 to 2 only): Subjects with other solid tumors (OT) who have received at least 2 lines of standard therapy, including adjuvant/neoadjuvant treatment, or whose cancer is considered refractory to standard of care or for which no standard treatment is available. As applicable per standard of care, subjects with HER2 and/or PD-L1 positive tumors must have received targeted treatment in their prior lines of therapy, and subjects with MSI-H or dMMR positive tumors must have received immune checkpoint inhibitor. 5. Agree to provide existing tumor samples (formalin-fixed paraffin-embedded [FFPE] tissue block or slides) from primary or metastatic sites obtained within 2 years or FFPE block from fresh biopsy (see details in Section 7.1) for tissue-based evaluation of CLDN18.2 expression 6. Has at least one measurable lesion based on RECIST (Response Evaluation Criteria in Solid Tumors) V1.1 7. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 8. Toxicity of previous antitumor therapy has returned to Grade ≤1 as defined by NCI CTCAE V5.0, except for alopecia and endocrinopathies controlled by replacement therapy that must be Grade ≤2 9. Has no serious cardiac dysfunction, left ventricular ejection fraction ≥50% 10. Has adequate organ function before enrollment, defined as:
    1. Marrow function: Absolute neutrophil count (ANC) ≥1.2×109/L, platelet count (PLT) ≥100×109/L, hemoglobin (Hb) ≥90 g/L 2. Hepatic function: Total bilirubin (TBIL) ≤1.5 ULN, AST and ALT without liver metastasis ≤2.5 ULN, AST and ALT with liver metastasis ≤5.0 ULN 3. Renal function: Creatinine clearance ≥60 mL/min (Cockcroft-Gault equation) 11. Coagulation parameters: International normalized ratio (INR) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5 ULN 12. Urine protein ≤2+ or ≤1000 mg/24 hours 13. Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception (defined in Appendix E) during the course of the study and for 7 months after the last dose of study treatment. An additional contraceptive method, such as a barrier method (eg, condom), is recommended. 14. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and must be nonlactating. Female subjects are considered WOCBP unless one of the following criteria are met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman >45 years old in the absence of other biological or physiological causes. In addition, females <55 years old must have a serum follicle stimulating hormone (FSH) level >40 mIU/mL to confirm menopause.
    Exclusion Criteria:
    1. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other antitumor therapy within 2 weeks or 5 half-lives (whichever is longer) prior to the first administration; major surgery within 4 weeks prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration 2. Subjects with history of severe heart disease, such as symptomatic congestive heart failure (CHF) ≥ Grade 2 (CTCAE 5.0), New York Heart Association (NYHA) ≥ Grade 2 heart failure, history of transmural myocardial infarction, unstable angina pectoris, etc. 3. Subjects with prolonged QT interval (QTcF >470 msec), complete left bundle branch block, Grade 3 atrioventricular block 4. Active autoimmune diseases and inflammatory diseases, such as systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, etc., except for type 1 diabetes, hypothyroidism that can be controlled by standard of care treatment, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis) 5. Subjects with other prior or concurrent malignant tumors diagnosed within 5 years prior to the first administration considered to be in remission, with the following exceptions: basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after radical resection, or other malignancy in which treatment does not interfere with the safety or efficacy assessment of the investigational product 6. Subjects with poorly controlled hypertension by two types of antihypertensive drugs (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) 7. Subjects who have Grade 3 lung disease defined according to NCI CTCAE v5.0, or a history of interstitial lung disease (ILD) 8. Subjects with stroke (including transient ischemic attack [TIA]), myocardial infarction, or other ischemic event or thromboembolic event (eg, deep vein thrombosis, pulmonary embolism [DVT/PE]) within 6 months before randomization except for those with a diagnosis of DVT who are stable and receiving treatment with adequate anticoagulant therapy for at least 3 weeks before randomization 9. Subjects with primary tumors in the central nervous system (CNS) and active or untreated CNS metastases and/or carcinomatous meningitis should be excluded.
    Patients with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks and have no evidence of new or enlarging brain metastases and no requirements for corticosteroids 14 days prior to dosing with the investigational product (IP). Patients on low dose corticosteroids (<20 mg prednisone or equivalent/day) may participate. 10. Subjects with pre-existing ≥Grade 2 peripheral neuropathy 11. Subjects who have a history of allergies to recombinant humanized antibodies or human-mouse chimeric antibodies or any of the components of BL-M05D1 12. Subjects who have received treatment with anthracyclines with a cumulative dose exceeding 360 mg/m2 13. Known human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number > the lower limit of detection) or active hepatitis C virus infection (HCV antibody positive and HCV-RNA > the lower limit of detection) 14. Subjects with active infections requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc., that require use of intravenous antibiotics, antiviral drugs, or antifungal drugs during the study period. 15. Participated in another clinical trial within 4 weeks or two half-lives (whichever is longer) prior to first dose of study treatment 16. Subjects who are pregnant or breastfeeding 17. Other conditions that the investigator believes are not suitable for participating in this clinical trial.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

    • STUDY_DIRECTOR: Sarah Tannenbaum, SystImmune Inc.

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available

    Treat yourself

    Let Us Take Care Of You

    BOOK AN APPOINTMENT ⟶
    footer logo

    About

    Events

    Fundraising

    Contact Us

    Facebook-f Instagram

    NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.

    The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.

    Copyright © 2025 – National Pancreatic Cancer Foundation | All Rights Reserved

    Make-A-Will Month

    Snag 6508be92
    Learn More
    Donate Now Online
    Other Ways to Donate